Rosiglitazone

Generic Name: Rosiglitazone

Brand Names: Avandamet, Avandia

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₁₉N_₃O_₃S

CAS Number: 122320-73-4

Unique Ingredient Identifier: 05V02F2KDG

Background: Rosiglitazone is an anti-diabetic drug in the thiazolidinedione class of drugs. It is marketed by the pharmaceutical company GlaxoSmithKline as a stand-alone drug (Avandia) and in combination with metformin (Avandamet) or with glimepiride (Avandaryl). Like other thiazolidinediones, the mechanism of action of rosiglitazone is by activation of the intracellular receptor class of the peroxisome proliferator-activated receptors (PPARs), specifically PPARγ. Rosiglitazone is a selective ligand of PPARγ, and has no PPARα-binding action. Apart from its effect on insulin resistance, it appears to have an anti-inflammatory effect: nuclear factor kappa-B (NFκB) levels fall and inhibitor (IκB) levels increase in patients on rosiglitazone. Recent research has suggested that rosiglitazone may also be of benefit to a subset of patients with Alzheimer's disease not expressing the ApoE4 allele. This is the subject of a clinical trial currently underway.

Indication: Rosiglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Associated Conditions: Type 2 Diabetes Mellitus

Associated Therapies: -

Clinical Trials

Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer's Disease

Phase 2

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: Rosiglitazone
Other: Placebo

First Posted Date: 2005-12-14

Last Posted Date: 2020-11-18

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 80

Registration Number: NCT00265148

Locations: 🇬🇧
GSK Investigational Site, West End, Southampton, United Kingdom

Markers and Mechanisms of Vascular Disease in Type II Diabetes

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Rosiglitazone

First Posted Date: 2005-11-21

Last Posted Date: 2014-05-23

Lead Sponsor: US Department of Veterans Affairs

Target Recruit Count: 298

Registration Number: NCT00256646

Locations: 🇺🇸
Southern Arizona VA Health Care System, Tucson, Tucson, Arizona, United States
🇺🇸
VA Medical Center, Lexington, Lexington, Kentucky, United States
🇺🇸
VA Medical Center, Omaha, Omaha, Nebraska, United States

and more 14 locations

Insulin Resistance in Non-alcoholic Fatty Liver Disease

Not Applicable

Terminated

Conditions: Fatty Liver
Insulin Resistance

Interventions: Drug: rosiglitazone
Drug: placebo for rosiglitazone
Drug: fenofibrate
Drug: placebo for fenofibrate

First Posted Date: 2005-11-11

Last Posted Date: 2014-08-20

Lead Sponsor: US Department of Veterans Affairs

Target Recruit Count: 13

Registration Number: NCT00252499

Locations: 🇺🇸
VA Puget Sound Health Care System, Seattle, Seattle, Washington, United States

Rosiglitazone Effects on Cognition for Adults in Later Life

Phase 2

Conditions: Mild Cognitive Impairment

Interventions: Drug: Rosiglitazone

First Posted Date: 2005-10-20

Last Posted Date: 2011-08-05

Lead Sponsor: University of Washington

Target Recruit Count: 120

Registration Number: NCT00242593

Locations: 🇺🇸
UCLA Alzheimer's Disease Center, Los Angeles, California, United States
🇺🇸
University of Washington/VA Puget Sound Health Care System, Seattle/Tacoma, Washington, United States
🇺🇸
Banner Alzheimer Institute, Phoenix, Arizona, United States